The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

LI.d

Myocarditis (can be fulminant)

Publications

Cesa K, Cunningham C, Harris T, Sunseri W

A Review of Extraintestinal Manifestations & Medication-Induced Myocarditis and Pericarditis in Pediatric Inflammatory Bowel Disease.

Cureus 2022 Jun;14;e26366 — 2022 Jun — e26366

—

[Childhood Interstitial Lung Disease in Infancy. Classification, diagnosis and management].

Archivos argentinos de pediatria 2019 Apr;117;S120-S134 — 2019 Apr

Lezcano-Gort LE, Gómez-Barrado JJ, Mogollón-Jiménez MV, Garcipérez-de-Vargas-Díaz FJ

Hypersensitivity perimyocarditis after the first dose of infliximab.

Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva 2015 Apr;107;249 — 2015 Apr — 249

Slattery E, Ismail N, Sheridan J, Eustace K, Harewood G, Patchett S

Myocarditis associated with infliximab: a case report and review of the literature.

Inflammatory bowel diseases 2011 Jul;17;1633-4 — 2011 Jul — 1633-4